Horizon Investments LLC Has $13.34 Million Holdings in United Therapeutics Corporation $UTHR

Key Points

• Horizon Investments LLC increased its stake in United Therapeutics by 28.3% to 27,382 shares, valued at about $13.34 million (roughly 0.06% of the company) at the end of the quarter.
• Multiple analysts raised price targets (e.g., UBS to $705, RBC to $643), leaving a consensus "Moderate Buy" rating and an average target price of $601.50.
• Insiders have been net sellers recently— the CFO sold 10,000 shares and a director sold 2,910 shares— with insiders offloading 469,205 shares worth about $253.9 million over the past 90 days.

Horizon Investments LLC lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 28.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,382 shares of the biotechnology company's stock after purchasing an additional 6,037 shares during the period. Horizon Investments LLC owned approximately 0.06% of United Therapeutics worth $13,342,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Danske Bank A S boosted its position in United Therapeutics by 21.8% in the 4th quarter. Danske Bank A S now owns 19,473 shares of the biotechnology company's stock valued at $9,488,000 after buying an additional 3,484 shares during the last quarter. GenTrust LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at $221,000. Citizens Financial Group Inc. RI acquired a new position in shares of United Therapeutics during the fourth quarter valued at $209,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Finally, Sage Rhino Capital LLC acquired a new stake in United Therapeutics in the fourth quarter worth about $220,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. Bank of America raised their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 31st. Finally, Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $601.50.

Insiders Place Their Bets

In other news, Director Christopher Patusky sold 2,910 shares of the company's stock in a transaction that occurred on Friday, April 24th. The shares were sold at an average price of $569.00, for a total value of $1,655,790.00. Following the completion of the transaction, the director owned 1,490 shares in the company, valued at $847,810. This represents a 66.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $572.61, for a total transaction of $5,726,100.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company's stock, valued at $10,808,586.36. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 469,205 shares of company stock worth $253,860,521 over the last ninety days. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $570.40 on Friday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89. The stock has a market cap of $25.00 billion, a P/E ratio of 20.44, a P/E/G ratio of 1.63 and a beta of 0.75. The firm has a 50 day moving average price of $543.83 and a 200 day moving average price of $497.42.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. During the same period last year, the firm posted $6.19 earnings per share. The business's quarterly revenue was up 7.4% compared to the same quarter last year. Analysts predict that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.